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colon (3) pelvic side wall (12) presarcal (5) central pelvis (2) presarcal and pelvic side wall (1) pubic area (1) 90. CTV: clinical target volume, GTV: gross tumour volume, IGRT: image guided radiotherapy, MV: megavoltage, NR: not reported, PTV: planning target volume, VMAT: volumetric modulated arc therapy, * the group distinguished patients as those treated with SABR and those who received image-guided intensity modulated therapy or image-guided 3 dimensional conformal radiotherapy-all doses were extremely hypofractionated (5-6Gy per fraction) and delivered with image guidance and so were considered as SABR for this review. CTCAE: Common Terminology Criteria for Adverse Events, EQD2: equivalent dose in 2Gy fractions, NR: not reported, LDR: low dose rate, RTOG: Radiation Therapy Oncology Group *Note: cumulative doses have largely been calculated by simple summing of median and range of values from initial radiotherapy and subsequent re-irradiation SABR prescription doses, and are not based on individual patient data, which is frequently not available. This approach assumes the re-irradiated lesion was located within the high dose region of the original dose distribution. 
Detailed discussion regarding re-irradiation organ at risk constraints
Determining the most appropriate constraints for pelvic Stereotactic Ablative Radiotherapy (SABR) re-irradiation is one of the most challenging components of re-irradiation. Table 8 illustrates three strategies for determining organ at risk (OAR) constraints for pelvic SABR re-irradiation using a variety of first irradiation normal tissue doses. The first strategy uses the same cumulative constraints as described by Abusaris et al 6 . The second and third strategies use conventional first irradiation dose constraints as cumulative constraints, initially assuming no repair and then assuming 50% repair between irradiations. To utilise cumulative constraints, the original dose must be converted to the EQD2 or BED (e.g. using =3Gy) and subtracted from the cumulative constraint in EQD2 or BED (example of calculation provided in Figure 1 ). In the situation of 50% repair, 50% of the original dose is subtracted from the cumulative constraint. The remaining dose is what is remaining for the OAR for SABR reirradiation in EQD2 or BED Gy This is converted to the equivalent dose in the required number of fractions for SABR delivery (5-fraction SABR in these examples). For comparison, the final column in Table 2 shows the constraints contained in the report of the American Association of Physicists in Medicine (AAPM) for pelvic SABR, intended for first irradiation 18 . Intuitively, it would seem reasonable that constraints for SABR re-irradiation do not exceed those for first SABR irradiation. The principal pelvic OARs are considered below.
As discussed in the main paper, for small bowel, the most conservative and thus safest approach to re-irradiation would be to use traditional first irradiation constraints as cumulative constraints without allowing any repair. While this would be the preferred strategy, the dose remaining for SABR re-irradiation of small bowel could be prohibitively small, particularly in cases where the small bowel is within or close to the PTV. This method for defining constraints may be unnecessarily conservative if a degree of normal tissue repair occurs following first irradiation. The constraints described by Abusaris et al, in contrast, are considerably more lenient 6 . Abusaris et al adopted these constraints based on the fact that the re-irradiated volume was likely to be small, although how the actual cumulative values were determined was not discussed. Despite this leniency, no high-grade toxicity was reported. It can also be seen from the table that the AAPM SABR constraints for small bowel for first irradiation are more conservative than those used by Abusaris et al for re-irradiation 6, 18 . When traditional constraints are used in a cumulative manner, but allowing 50% repair, the remaining dose, in the most part, remains more conservative than the constraints used by Abusairs et al.
Considering all of the above, the preferred option for small bowel re-irradiation would be to meet the traditional constraints, used in a cumulative manner, without including repair first choice best case scenario )f this is not possible then an alternative strategy must be adopted. As a pragmatic compromise, to allow more freedom in dose prescription, yet remain more conservative than the constraints described by Abusaris et al, the traditional constraints could be used in a cumulative manner, but including a degree of recovery, which could be influenced by the interval between first and second irradiation. If using this approach, however, it must be accepted that the assumption of 50% recovery, or otherwise, is empirical rather than evidence based. Alongside this cumulative constraint, the AAPM small bowel volume-based constraint for first SABR should also be respected (19.5Gy to <5cm 3 ), and the lower of the two maximum point doses (i.e. AAPM vs that calculated when allowing a degree of recovery) should be selected as the maximum dose constraint.
For the rectum and bladder, drawing comparisons between constraints is more difficult as these apply over different volumes and, for the bladder, the structure also differs (i.e. whole bladder vs. bladder wall). If the rectum and bladder are both relatively empty prior to re-irradiation (thus 10cm 3 of rectum or bladder (to which the Abusairs et al constraints apply) is likely to be a larger volume than 15% of rectum or bladder (to which the conventional constraints apply; [19] ), these appear more conservative than the APPM constraints.
Again, meeting the traditional constraints, used cumulatively without any repair, would be the preferred strategy, but if not possible, as a pragmatic compromise, the traditional constraints could be used cumulatively, allowing a degree of repair.
The correct approach to defining OAR constraints for SABR pelvic re-irradiation is unknown. Ideally traditional constraints would be used in a cumulative manner, without repair, and the remaining dose would not be exceeded by the re-irradiation SABR plan if feasible. As mentioned above, such constraints may be prohibitive to delivering meaningful SABR doses. The pragmatic, alternative approach outlined above, is summarised in Table 9 , but in more detail than in Table 2 in the main document. Based on the above discussion and the values in repair. Previous plans should always be reviewed, and ideally formally combined to evaluate the normal tissue doses. For previous irradiation doses of greater than about 54Gy and/or when brachytherapy has been given to the region requiring re-irradiation, the re-irradiation dose prescriptions may need to be more restrictive.
There are huge uncertainties in the above and this discussion aims to illustrate options rather than provide definitive solutions. For some exploratory calculations we included 50% repair. As before, this figure is more empirical than evidence based. Length of time between irradiation may influence the degree of repair, although clinical evidence to determine such factors for normal pelvic tissues is severely lacking 20 . As mentioned in the main document, it should also be noted that additional patient related factors such as diabetes and vascular disease may also contribute to the risk of toxicity following reirradiation, although there is insufficient evidence to know how these should be incorporated. The uncertainties involved merely highlight the importance of high quality prospective evaluation of future patients, including dosimetric analysis.
Going forward, when there is more prospective data to guide constraints, these should be to absolute volumes rather than percentage volumes to reduce the impact of contouring variability 21, 22 . The achievable prescription dose is unlikely to be higher than this if organ at risk within and close to PTV.
Note. It is intentional that it is the maximum point dose from the original plan is subtracted from the cumulative dose constraint even in the setting of a constraint to a maximum absolute volume (in this case 10cm 3 ) as this is a more conservative approach than recording the dose to the absolute volume specified in the constraint.
This method assumes that a full 3-dimensional means of combining former and reirradiation plans, with adaptation for anatomical changes and fractionation correction, as described in the main paper, is unavailable.
